SCHEMBL16985243

SCHEMBL16985243

CS(=O)(=O)c1cc2cc(F)ccc2o1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.51
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA9 Q16790 1/20 0.51
CCR2 P41597 1/20 0.43
ATM Q13315 1/20 0.40
APP P05067 1/20 0.39
PKM P14618 2/20 0.38
LMNA P02545 1/20 0.38
MKNK1 Q9BUB5 1/20 0.37
PGR P06401 2/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18233460 0.82 CA2 (0.51) CA2CA12CA1CA9CCR2
SCHEMBL18223712 0.82 CA2 (0.51) CA2CA12CA1CA9ATM
SCHEMBL18223609 0.78 TRPA1 (0.45) CA2CA12CA1CA9CCR2
SCHEMBL6683885 0.76 CYP2A6 (0.46) CA2CCR2CHRM2CHRM4CHRM5
SCHEMBL16985241 0.76 CA2 (0.67) CA2CA12CA1CA9CCR2
SCHEMBL18233477 0.73 TRPA1 (0.50) CA2CA12CA1CA9CCR2
SCHEMBL18233472 0.73 ATM (0.42) CA2CA12CA1CA9ATM
SCHEMBL20577822 0.73 TRPA1 (0.50) CA2CA12CA1CA9CCR2
SCHEMBL18233473 0.72 CA2 (0.39) CA2CA12CA1CA9ATM
SCHEMBL18233471 0.72 CA2 (0.42) CA2CA12CA1CA9ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same EA PHARMA CO., LTD. (JP) 2020-04-21 US disclosed
US-20180162844-A1 CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME EA PHARMA CO., LTD. (JP) 2018-06-14 US disclosed
US-20180162844-A1 CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME EA PHARMA CO., LTD. (JP) 2018-06-14 US disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed
WO-2015115507-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME 味の素株式会社 2015-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME TRPA1, TRPV1, TRPV2 CA2 210/4885CA12 2393/4885CA1 1394/4885
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same TRPA1, TRPV1, TRPV2 CA2 210/4885CA12 2393/4885CA1 1394/4885
US-20180162844-A1 CYCLOPROPANE DERIVATIVE AND DRUG CONTAINING SAME TRPA1, TRPV1, TRPV2 CA2 834/4885CA12 4355/4885CA1 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.